CS
CVAC

Credit Suisse’s CureVac CVAC Stock Holding History

Credit Suisse’s Portfolio CVAC Stock Details CVAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-47,600
Closed -$2.6M – 4526
2021
Q3 		$2.6M Buy
+47,600
New +$2.87M ﹤0.01% 2612

Other funds holding CVAC

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Credit Suisse's CVAC Position: Q1 2024 in Review

Credit Suisse reduced its CureVac (CVAC) stake by 57% in Q1 2024, selling an estimated $611K and leaving 129,787 shares worth $393K. The position accounts for ﹤0.01% of the portfolio, ranked #2736.

Credit Suisse first reported a position in CVAC in Q2 2021 and has held it in 12 quarters since. The position peaked at $3.09M in Q2 2023. 90 funds tracked by Wall St. Rank hold CVAC as of Q1 2024.

  • Credit Suisse held 129,787 shares of CureVac worth $393K as of Q1 2024.
  • Credit Suisse sold 174,072 CureVac shares in Q1 2024, an estimated $611K.
  • CureVac made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2736 holding.
  • Credit Suisse first reported a position in CureVac in Q2 2021 and has held it in 12 quarters since.
  • Credit Suisse's CureVac position peaked at $3.09M in Q2 2023.
  • 90 funds tracked by Wall St. Rank held CureVac as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.